Trial Profile

Pharmacokinetics, Safety and Tolerability of Different Oral Doses of Afatinib, in Subjects With Mild to Moderate Hepatic Impairment Compared to Healthy Subjects - a Phase I, Single-dose, Open-label, Dose-escalation Study in a Matched Group Design.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary)
Indications Breast cancer; Colorectal cancer; Glioblastoma; Head and neck cancer; Non-small cell lung cancer; Prostate cancer
Focus Pharmacokinetics
Sponsors Boehringer Ingelheim Pharmaceuticals

28 Sep 2012 Results presented at the European Society for Medical Oncology meeting, according to a Boehringer Ingelheim media release.
08 Feb 2012 Actual patient number (35) added as reported by ClinicalTrials.gov.
08 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com